Cardiovascular Systems, Inc. CSII reported adjusted loss per share of a penny in second-quarter fiscal 2018, against the year-ago quarter’s adjusted earnings of 3 cents.
The figure was narrower than the earlier guided range of loss per share of 6-3 cents. The figure also compared favorably with the Zacks Consensus Estimate of a loss of 4 cents.
Cardiovascular Systems recorded revenues of $52.6 million in the fiscal second quarter, marking a year-over-year increase of 5.1%. Also, the figure was within the guided range of $52.5-$54 million. However, revenues missed the Zacks Consensus Estimate of $53.3 million.
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise
Cardiovascular Systems, Inc. Price, Consensus and EPS Surprise | Cardiovascular Systems, Inc. Quote
Coronary device revenues increased 3.5% year over year to $13.4 million. To date, Cardiovascular Systems has sold over 3,56,000 devices to leading institutions in the United States
Meanwhile, peripheral device revenues rose 5.8% to $39.2 million on a year-over-year basis. The company added 29 new peripheral accounts and 30 coronary accounts in the fiscal second quarter.
Gross margin in the reported quarter was 81.9%, up 20 basis points (bps) year over year.
Meanwhile, selling and administrative (SG&A) expenses contracted 8.9% to $37 million and research and development (R&D) expenses were up 10.2% to $6.4 million. Resultantly, adjusted operating expenses were up 9.1% to $43.4 million.
Per management, operating expenses were lower than the earlier provided guidance due to reduced incentive compensation and payroll expenses. Operating loss was around $0.3 million, against operating income of $1.1 million in the year-ago quarter.
The company exited the second quarter of fiscal 2018 with cash and cash equivalents of $107.3 million, compared with $104.7 million at the end of preceding quarter. The company has no long term debt.
Cardiovascular Systems updated its fiscal 2018 revenue guidance to the range of $215-$219 million, down from $226-$233 million. The current Zacks Consensus Estimate for fiscal 2018 revenues is pegged at $225.3 million, below the company’s guided range.
The company expects revenues in the range of $55-$56.5 million for third-quarter fiscal 2018. The current Zacks Consensus Estimate is pegged at $59.5 million, above the company’s guided range.
Moreover, the company expects gross profit to account for 81% of revenues, while operating expenses are estimated at around $45.5 million for third-quarter fiscal 2018.
The company expects to incur net loss of $0.9 million to $0.0 million. Adjusted earnings per share is expected to be between negative 3 cents and breakeven. The current Zacks Consensus Estimate is pegged earnings at 3 cents, above the company’s guided range.
Cardiovascular Systems exited second-quarter fiscal 2018 on a solid notewith year-over-year increase in both Coronary device and peripheral device segment. Overall revenues increased on a year-over-year basis on strength in both the company segments. Also, the expansion is gross margin buoys optimism. The company is putting efforts in product innovation through R&D investments. On the flipside, Cardiovascular Systems faces cutthroat competition in the niche space. Cardio Vascular incurred net loss in the recently-reported second quarter. In fact, the company has a long history of net losses since inception.
Zacks Rank & Key Releases
Cardiovascular Systems has a Zacks Rank #3 (Hold).
A few better-ranked stocks that reported solid results this earnings season are PetMed Express PETS, PerkinElmer PKI and Becton, Dickinson and Company BDX. While PetMed sports a Zacks Rank #1 (Strong Buy), PerkinElmer and Becton, Dickinson carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed recently reported third-quarter fiscal 2018 results. Adjusted earnings per share were 44 cents, up 88.3% from the prior-year quarter. Revenues rose 13.7% on a year-over-year basis to $60.1 million.
PerkinElmer reported fourth-quarter 2017 adjusted earnings per share of 97 cents. Adjusted revenues were approximately $641.6 million, up from $567 million in the year-ago quarter.
Becton, Dickinson reported first-quarter 2018 adjusted earnings per share of $2.48, up 3.9% at constant currency. Revenues totaled $3.08 billion, up 3.7% at constant currency.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PetMed Express, Inc. (PETS) : Free Stock Analysis Report
PerkinElmer, Inc. (PKI) : Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research